Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...
R&S has launched the NGT3600 series of DC power supplies, delivering up to 3.6 kW for a wide range of test and measurement ...
Thinking Techie] takes us back to basics in a recent video explaining how magnets, coils, brushed DC motors, and brushless DC ...
Rotating equipment operating near structural natural frequencies is prone to resonance, resulting in elevated vibration ...
A compact upgrade that delivers huge results! Watch how this fire-starting essential performs in the field. #OutdoorGear #SurvivalTools #FireStartingTips #BushcraftLife #Uberleben Five key moments ...
DRIVERS who have held their learner permits for more than four years will be required to sit a driving test to renew them, under new regulations. Minister of State for Road Safety Sean Canney signed ...
The FDA has said it intends to reduce or replace animal testing of some medicines, including monoclonal antibodies, with other methods that it hopes will be more relevant to human physiology. Among ...
Model 3. Nathan's Tesla is rewriting the book on EV longevity. With 88% battery capacity retained, this Tesla proves electric cars can last the distance. Dive into the amazing story of his first EV ...
Hosted on MSN
Alector’s Phase 3 Trial of Latozinemab Fails to Meet Efficacy Endpoints in FTD-GRN Study
KING OF PRUSSIA, PA — Alector, Inc. announced that its experimental therapy latozinemab failed to meet primary efficacy and safety endpoints in a Phase 3 clinical trial evaluating the drug as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results